Ganirelix Acetate is a synthetic gonadotropin-releasing hormone (GnRH) receptor antagonist used in reproductive medicine. It competitively blocks GnRH receptors in the pituitary gland, producing rapid suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.
Ganirelix Acetate is primarily used during controlled ovarian stimulation in assisted reproductive technology (ART), including IVF protocols, to prevent a premature LH surge and premature ovulation.
Ganirelix Acetate is a specialized synthetic peptide API used in pharmaceutical formulations for fertility treatment. It is administered by subcutaneous injection and provides controlled suppression of pituitary gonadotropin secretion during ovarian stimulation.
CAS Number: 123246-29-5
Molecular Formula: C80H113ClN18O13·xC2H4O2
Molecular Weight: Approximately 1570.34 g/mol for the peptide moiety; the final molecular mass varies with acetate content and hydration state.
Drug Class: GnRH Receptor Antagonist
Therapeutic Class: Gonadotropin Suppressant
Therapeutic Area: Reproductive Endocrinology / Fertility
Ganirelix Acetate competitively antagonizes GnRH receptors in the anterior pituitary. This inhibits GnRH-mediated secretion of LH and FSH. Suppression of LH prevents a premature LH surge and helps control the timing of ovulation during controlled ovarian stimulation.
Ganirelix Acetate is used in assisted reproductive technology, particularly during controlled ovarian stimulation, to reduce the risk of premature LH surges and premature ovulation.
During ovarian stimulation, premature elevation of LH can result in premature ovulation. Ganirelix Acetate provides rapid GnRH receptor blockade, allowing clinicians to better control the timing of ovulation and oocyte retrieval.
Ganirelix Acetate is a synthetic decapeptide GnRH antagonist containing multiple amino-acid residues. It is supplied as an acetate salt and is generally handled as a peptide pharmaceutical material requiring specialized purification and analytical characterization.
Ganirelix Acetate API quality assessment may include peptide identity by LC-MS and peptide mapping, purity by RP-HPLC, assay, related peptides, water content, residual solvents, acetate content, elemental impurities, endotoxin and other applicable peptide-specific tests.
Ganirelix Acetate should be stored in tightly closed containers under controlled pharmaceutical conditions and protected from excessive heat, moisture and direct light. Exact storage conditions should follow validated stability data and the applicable product-specific specification.
Ganirelix Acetate is an important peptide API in reproductive endocrinology. Its selective GnRH receptor antagonism provides a mechanism for controlling pituitary gonadotropin secretion during fertility-treatment protocols.
Ganirelix Acetate is a synthetic GnRH receptor antagonist peptide used primarily in controlled ovarian stimulation during assisted reproductive procedures. It suppresses LH and FSH secretion by competitively blocking GnRH receptors and helps prevent premature LH surges.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 95.0% – 105.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 1.0% |
| Total Impurities | NMT 5.0% |
| Water Content | NMT 0.5% |